| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-06-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-06-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-12-2025 | 12-31-2024 | 10-K | |
| 4 | 11-07-2024 | 09-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Danielle Brill initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Pri...
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focu...
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, conges...